SK286352B6 - Use of fumaric acid derivatives in transplant medicine - Google Patents

Use of fumaric acid derivatives in transplant medicine Download PDF

Info

Publication number: SK286352B6
Authority: SK; Slovakia
Prior art keywords: fumaric acid; fumarate; use according; weight; calcium
Prior art date: 1998-08-31

Application number

SK257-2001A

Other languages

English (en)

Slovak (sk)

Other versions

SK2572001A3 (en

Inventor

Rajendra Kumar Joshi

Hans-Peter Strebel

Original Assignee

Fumapharm Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-31

Filing date

1999-08-20

Publication date

2008-07-07

1999-08-20 Application filed by Fumapharm Ag filed Critical Fumapharm Ag

2002-05-09 Publication of SK2572001A3 publication Critical patent/SK2572001A3/sk

2008-07-07 Publication of SK286352B6 publication Critical patent/SK286352B6/sk

Links

239000003814 drug Substances 0.000 title claims abstract description 31
150000002237 fumaric acid derivatives Chemical class 0.000 title description 8
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 78
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 48
239000001530 fumaric acid Substances 0.000 claims abstract description 34
238000002360 preparation method Methods 0.000 claims abstract description 27
150000003839 salts Chemical class 0.000 claims abstract description 21
239000002253 acid Substances 0.000 claims abstract description 19
238000006243 chemical reaction Methods 0.000 claims abstract description 18
229930182912 cyclosporin Natural products 0.000 claims abstract description 8
239000003018 immunosuppressive agent Substances 0.000 claims abstract description 7
239000004480 active ingredient Substances 0.000 claims description 35
239000002775 capsule Substances 0.000 claims description 32
239000003826 tablet Substances 0.000 claims description 32
239000011248 coating agent Substances 0.000 claims description 26
238000000576 coating method Methods 0.000 claims description 26
239000008188 pellet Substances 0.000 claims description 26
150000002148 esters Chemical class 0.000 claims description 19
LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims description 16
229960004419 dimethyl fumarate Drugs 0.000 claims description 16
-1 alkyl hydrogen carbonates Chemical class 0.000 claims description 15
239000011575 calcium Substances 0.000 claims description 15
239000008187 granular material Substances 0.000 claims description 15
238000011282 treatment Methods 0.000 claims description 15
206010052779 Transplant rejections Diseases 0.000 claims description 13
NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 claims description 13
150000001768 cations Chemical class 0.000 claims description 12
239000011701 zinc Substances 0.000 claims description 12
XLYMOEINVGRTEX-ONEGZZNKSA-N (e)-4-ethoxy-4-oxobut-2-enoic acid Chemical compound CCOC(=O)\C=C\C(O)=O XLYMOEINVGRTEX-ONEGZZNKSA-N 0.000 claims description 11
239000011777 magnesium Substances 0.000 claims description 11
NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 claims description 10
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 9
229930105110 Cyclosporin A Natural products 0.000 claims description 9
108010036949 Cyclosporine Proteins 0.000 claims description 9
229960001265 ciclosporin Drugs 0.000 claims description 9
229910052791 calcium Inorganic materials 0.000 claims description 8
239000007903 gelatin capsule Substances 0.000 claims description 7
229910052749 magnesium Inorganic materials 0.000 claims description 7
210000000056 organ Anatomy 0.000 claims description 7
229910052725 zinc Inorganic materials 0.000 claims description 7
229940125721 immunosuppressive agent Drugs 0.000 claims description 6
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
159000000007 calcium salts Chemical group 0.000 claims description 5
229910052708 sodium Inorganic materials 0.000 claims description 5
239000001749 Calcium fumarate Substances 0.000 claims description 4
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
235000019296 calcium fumarate Nutrition 0.000 claims description 4
XLYMOEINVGRTEX-UHFFFAOYSA-N fumaric acid monoethyl ester Natural products CCOC(=O)C=CC(O)=O XLYMOEINVGRTEX-UHFFFAOYSA-N 0.000 claims description 4
229910052744 lithium Inorganic materials 0.000 claims description 4
206010009944 Colon cancer Diseases 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 3
229910052742 iron Inorganic materials 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
125000000896 monocarboxylic acid group Chemical group 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
229940124531 pharmaceutical excipient Drugs 0.000 claims description 3
229910052700 potassium Inorganic materials 0.000 claims description 3
RWYRUDPAALLKPX-UHFFFAOYSA-N 2,2-difluoro-n-methylethanamine;hydrochloride Chemical compound Cl.CNCC(F)F RWYRUDPAALLKPX-UHFFFAOYSA-N 0.000 claims description 2
XJUWMMYUOLYYJE-TYYBGVCCSA-N (e)-but-2-enedioic acid;calcium Chemical compound [Ca].OC(=O)\C=C\C(O)=O XJUWMMYUOLYYJE-TYYBGVCCSA-N 0.000 claims 1
125000005907 alkyl ester group Chemical group 0.000 claims 1
210000004051 gastric juice Anatomy 0.000 claims 1
159000000003 magnesium salts Chemical class 0.000 claims 1
238000007911 parenteral administration Methods 0.000 claims 1
150000003751 zinc Chemical class 0.000 claims 1
HJSYJHHRQVHHMQ-TYYBGVCCSA-L zinc;(e)-but-2-enedioate Chemical compound [Zn+2].[O-]C(=O)\C=C\C([O-])=O HJSYJHHRQVHHMQ-TYYBGVCCSA-L 0.000 claims 1
108010036941 Cyclosporins Proteins 0.000 abstract description 3
229960003444 immunosuppressant agent Drugs 0.000 abstract 1
230000000116 mitigating effect Effects 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 description 67
229920000036 polyvinylpyrrolidone Polymers 0.000 description 26
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 26
230000001681 protective effect Effects 0.000 description 21
238000000034 method Methods 0.000 description 20
238000002054 transplantation Methods 0.000 description 19
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
239000008194 pharmaceutical composition Substances 0.000 description 18
239000001267 polyvinylpyrrolidone Substances 0.000 description 15
239000000243 solution Substances 0.000 description 14
210000004211 gastric acid Anatomy 0.000 description 13
239000000454 talc Substances 0.000 description 13
235000012222 talc Nutrition 0.000 description 13
229910052623 talc Inorganic materials 0.000 description 13
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 12
235000012239 silicon dioxide Nutrition 0.000 description 12
239000003981 vehicle Substances 0.000 description 12
241001465754 Metazoa Species 0.000 description 11
YRPQEKFZVJEVNK-SFRQHTGFSA-L calcium;(e)-4-methoxy-4-oxobut-2-enoate Chemical compound [Ca+2].COC(=O)\C=C\C([O-])=O.COC(=O)\C=C\C([O-])=O YRPQEKFZVJEVNK-SFRQHTGFSA-L 0.000 description 10
229920000168 Microcrystalline cellulose Polymers 0.000 description 9
210000003734 kidney Anatomy 0.000 description 9
235000019359 magnesium stearate Nutrition 0.000 description 9
229940016286 microcrystalline cellulose Drugs 0.000 description 9
235000019813 microcrystalline cellulose Nutrition 0.000 description 9
239000008108 microcrystalline cellulose Substances 0.000 description 9
229910002012 Aerosil® Inorganic materials 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
229920003080 Povidone K 25 Polymers 0.000 description 8
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 8
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 8
239000012071 phase Substances 0.000 description 8
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 8
239000007864 aqueous solution Substances 0.000 description 7
FWUIHQFQLSWYED-ONEGZZNKSA-N (e)-4-oxo-4-propan-2-yloxybut-2-enoic acid Chemical compound CC(C)OC(=O)\C=C\C(O)=O FWUIHQFQLSWYED-ONEGZZNKSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
229920000881 Modified starch Polymers 0.000 description 6
WOONQYHBMBCNDD-SYWGCQIGSA-L calcium;(e)-4-ethoxy-4-oxobut-2-enoate Chemical compound [Ca+2].CCOC(=O)\C=C\C([O-])=O.CCOC(=O)\C=C\C([O-])=O WOONQYHBMBCNDD-SYWGCQIGSA-L 0.000 description 6
230000001684 chronic effect Effects 0.000 description 6
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
235000019426 modified starch Nutrition 0.000 description 6
239000000843 powder Substances 0.000 description 6
238000005303 weighing Methods 0.000 description 6
201000004681 Psoriasis Diseases 0.000 description 5
229940079593 drug Drugs 0.000 description 5
238000001035 drying Methods 0.000 description 5
239000008385 outer phase Substances 0.000 description 5
239000007962 solid dispersion Substances 0.000 description 5
238000001694 spray drying Methods 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
239000004359 castor oil Substances 0.000 description 4
235000019438 castor oil Nutrition 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000009833 condensation Methods 0.000 description 4
230000005494 condensation Effects 0.000 description 4
239000002662 enteric coated tablet Substances 0.000 description 4
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
ZHLRSUSHKGQBNV-SYWGCQIGSA-L magnesium;(e)-4-ethoxy-4-oxobut-2-enoate Chemical compound [Mg+2].CCOC(=O)\C=C\C([O-])=O.CCOC(=O)\C=C\C([O-])=O ZHLRSUSHKGQBNV-SYWGCQIGSA-L 0.000 description 4
230000008569 process Effects 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
239000011734 sodium Substances 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
LBQUJVJZHVBJTO-UHFFFAOYSA-M C(C=CC(=O)[O-])(=O)OC.[Ca+] Chemical compound C(C=CC(=O)[O-])(=O)OC.[Ca+] LBQUJVJZHVBJTO-UHFFFAOYSA-M 0.000 description 3
229920000623 Cellulose acetate phthalate Polymers 0.000 description 3
229920003148 Eudragit® E polymer Polymers 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
NTIZJDJBGKXHHY-SQQVDAMQSA-M [Zn+].C(\C=C\C(=O)[O-])(=O)OC Chemical compound [Zn+].C(\C=C\C(=O)[O-])(=O)OC NTIZJDJBGKXHHY-SQQVDAMQSA-M 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
125000003158 alcohol group Chemical group 0.000 description 3
125000005233 alkylalcohol group Chemical group 0.000 description 3
NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229940081734 cellulose acetate phthalate Drugs 0.000 description 3
238000007906 compression Methods 0.000 description 3
230000006835 compression Effects 0.000 description 3
239000003246 corticosteroid Substances 0.000 description 3
229960001334 corticosteroids Drugs 0.000 description 3
229940109239 creatinine Drugs 0.000 description 3
150000005690 diesters Chemical class 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000002702 enteric coating Substances 0.000 description 3
238000009505 enteric coating Methods 0.000 description 3
235000013773 glyceryl triacetate Nutrition 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
239000008101 lactose Substances 0.000 description 3
229940005650 monomethyl fumarate Drugs 0.000 description 3
239000000902 placebo Substances 0.000 description 3
229940068196 placebo Drugs 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
230000004044 response Effects 0.000 description 3
239000011877 solvent mixture Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
229960002622 triacetin Drugs 0.000 description 3
XREUDNQQWZGRPS-SQQVDAMQSA-M C(\C=C\C(=O)[O-])(=O)OC.[Mg+] Chemical compound C(\C=C\C(=O)[O-])(=O)OC.[Mg+] XREUDNQQWZGRPS-SQQVDAMQSA-M 0.000 description 2
229920003137 Eudragit® S polymer Polymers 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
206010062016 Immunosuppression Diseases 0.000 description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
OGGYHLYPOPHHHH-BJILWQEISA-M [Ca+].CCOC(=O)\C=C\C([O-])=O Chemical compound [Ca+].CCOC(=O)\C=C\C([O-])=O OGGYHLYPOPHHHH-BJILWQEISA-M 0.000 description 2
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
230000000340 anti-metabolite Effects 0.000 description 2
229940100197 antimetabolite Drugs 0.000 description 2
239000002256 antimetabolite Substances 0.000 description 2
FNMTVMWFISHPEV-AATRIKPKSA-N dipropan-2-yl (e)-but-2-enedioate Chemical compound CC(C)OC(=O)\C=C\C(=O)OC(C)C FNMTVMWFISHPEV-AATRIKPKSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
159000000014 iron salts Chemical class 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
239000004014 plasticizer Substances 0.000 description 2
229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
159000000001 potassium salts Chemical class 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
230000003313 weakening effect Effects 0.000 description 2
DASOVGGSCVXZMC-SYWGCQIGSA-L zinc;(e)-4-ethoxy-4-oxobut-2-enoate Chemical compound [Zn+2].CCOC(=O)\C=C\C([O-])=O.CCOC(=O)\C=C\C([O-])=O DASOVGGSCVXZMC-SYWGCQIGSA-L 0.000 description 2
BSSNZUFKXJJCBG-OWOJBTEDSA-N (e)-but-2-enediamide Chemical compound NC(=O)\C=C\C(N)=O BSSNZUFKXJJCBG-OWOJBTEDSA-N 0.000 description 1
KYPOHTVBFVELTG-OWOJBTEDSA-N (e)-but-2-enedinitrile Chemical compound N#C\C=C\C#N KYPOHTVBFVELTG-OWOJBTEDSA-N 0.000 description 1
JDOZUYVDIAKODH-SNAWJCMRSA-N 4-o-ethyl 1-o-methyl (e)-but-2-enedioate Chemical compound CCOC(=O)\C=C\C(=O)OC JDOZUYVDIAKODH-SNAWJCMRSA-N 0.000 description 1
KMDOBCNQQPSXOY-UHFFFAOYSA-N 5-hydroxypentan-2-yl acetate Chemical compound CC(=O)OC(C)CCCO KMDOBCNQQPSXOY-UHFFFAOYSA-N 0.000 description 1
229930195730 Aflatoxin Natural products 0.000 description 1
XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
200000000007 Arterial disease Diseases 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
ZQTCPQDRGJBVKR-UHFFFAOYSA-M C(C=CC(=O)[O-])(=O)OCC.[Zn+] Chemical compound C(C=CC(=O)[O-])(=O)OCC.[Zn+] ZQTCPQDRGJBVKR-UHFFFAOYSA-M 0.000 description 1
229910014033 C-OH Inorganic materials 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
229910014570 C—OH Inorganic materials 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
201000009053 Neurodermatitis Diseases 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
229920003081 Povidone K 30 Polymers 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
KKGWFBLJHIPEFA-BJILWQEISA-M [Ca+].C(CC)OC(\C=C\C(=O)[O-])=O Chemical compound [Ca+].C(CC)OC(\C=C\C(=O)[O-])=O KKGWFBLJHIPEFA-BJILWQEISA-M 0.000 description 1
GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000005409 aflatoxin Substances 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
238000011316 allogeneic transplantation Methods 0.000 description 1
230000000781 anti-lymphocytic effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000002682 anti-psoriatic effect Effects 0.000 description 1
206010003230 arteritis Diseases 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
238000006065 biodegradation reaction Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000004665 defense response Effects 0.000 description 1
229940075894 denatured ethanol Drugs 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
BZCOSCNPHJNQBP-OWOJBTEDSA-N dihydroxyfumaric acid Chemical compound OC(=O)C(\O)=C(/O)C(O)=O BZCOSCNPHJNQBP-OWOJBTEDSA-N 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
230000029142 excretion Effects 0.000 description 1
210000003195 fascia Anatomy 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
239000008202 granule composition Substances 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
238000006317 isomerization reaction Methods 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
LZSWAZSVVKHFFY-SFRQHTGFSA-L magnesium;(e)-4-methoxy-4-oxobut-2-enoate Chemical compound [Mg+2].COC(=O)\C=C\C([O-])=O.COC(=O)\C=C\C([O-])=O LZSWAZSVVKHFFY-SFRQHTGFSA-L 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
229960004866 mycophenolate mofetil Drugs 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000005563 spheronization Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229960001967 tacrolimus Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000004102 tricarboxylic acid cycle Effects 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
230000036325 urinary excretion Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
SUGQOEANPAQNDQ-SFRQHTGFSA-L zinc;(e)-4-methoxy-4-oxobut-2-enoate Chemical compound [Zn+2].COC(=O)\C=C\C([O-])=O.COC(=O)\C=C\C([O-])=O SUGQOEANPAQNDQ-SFRQHTGFSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Surgery (AREA)
Transplantation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SK257-2001A 1998-08-31 1999-08-20 Use of fumaric acid derivatives in transplant medicine SK286352B6 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19839566A DE19839566C2 (de)	1998-08-31	1998-08-31	Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
PCT/EP1999/006110 WO2000012072A2 (de)	1998-08-31	1999-08-20	Verwendung von fumarsäurederivaten in der transplantationsmedizin

Publications (2)

Publication Number	Publication Date
SK2572001A3 SK2572001A3 (en)	2002-05-09
SK286352B6 true SK286352B6 (en)	2008-07-07

Family

ID=7879272

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK257-2001A SK286352B6 (en)	1998-08-31	1999-08-20	Use of fumaric acid derivatives in transplant medicine

Country Status (25)

Country	Link
US (1)	US6359003B1 (da)
EP (1)	EP1107749B1 (da)
JP (1)	JP3553883B2 (da)
CN (1)	CN1195511C (da)
AT (1)	ATE241353T1 (da)
AU (1)	AU746958B2 (da)
BG (1)	BG64435B1 (da)
BR (1)	BR9908722A (da)
CA (1)	CA2322188C (da)
DE (2)	DE19839566C2 (da)
DK (1)	DK1107749T3 (da)
EE (1)	EE05025B1 (da)
ES (1)	ES2195609T3 (da)
HK (1)	HK1040623B (da)
HU (1)	HUP0101854A3 (da)
IL (1)	IL138110A0 (da)
NO (1)	NO20006462L (da)
NZ (1)	NZ506573A (da)
PL (1)	PL198211B1 (da)
PT (1)	PT1107749E (da)
RS (1)	RS49780B (da)
RU (1)	RU2210364C2 (da)
SK (1)	SK286352B6 (da)
TR (1)	TR200002475T2 (da)
WO (1)	WO2000012072A2 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19853487A1 (de) *	1998-11-19	2000-05-25	Fumapharm Ag Muri	Verwendung von Dialkylfumaraten
US6342294B1 (en)	1999-08-12	2002-01-29	Bruce G. Ruefer	Composite PTFE article and method of manufacture
DE10000577A1 (de) *	2000-01-10	2001-07-26	Fumapharm Ag Muri	Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
DE10101307A1 (de) *	2001-01-12	2002-08-01	Fumapharm Ag Muri	Fumarsäurederivate als NF-kappaB-Inhibitor
AU2002219236B2 (en) *	2001-01-12	2006-02-09	Biogen International Gmbh	Fumaric acid amides
DE10217314A1 (de) *	2002-04-18	2003-11-13	Fumapharm Ag Muri	Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
WO2004112773A1 (en) *	2003-04-24	2004-12-29	Shin-Jen Shiao	Pharmaceutical compositions used for immune disease treatment and improvement
WO2005023241A1 (en) *	2003-09-09	2005-03-17	Fumapharm Ag	The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
DE10360869A1 (de) *	2003-09-09	2005-04-07	Fumapharm Ag	Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
SI2801354T1 (sl) *	2004-10-08	2017-07-31	Forward Pharma A/S	Farmacevtske sestave z nadzorovanim sproščanjem, ki zajemajo ester fumarne kisline
WO2007006307A2 (en) *	2005-07-07	2007-01-18	Aditech Pharma Ab	Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
US20100144651A1 (en) *	2005-07-07	2010-06-10	Aditech Pharma Ab	Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use
US20080299196A1 (en) *	2005-10-07	2008-12-04	Aditech Pharma Ab	Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
WO2007042035A2 (en) *	2005-10-07	2007-04-19	Aditech Pharma Ab	Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
DK2653873T3 (da)	2007-02-08	2022-07-25	Biogen Ma Inc	Sammensætninger og anvendelser til behandling af multipel sklerose
PT2139467T (pt) *	2007-02-08	2016-12-16	Biogen Ma Inc	Neuroproteção em doenças desmielinizantes
WO2009078754A1 (en) *	2007-12-19	2009-06-25	Ardenia Investments, Ltd.	Drug delivery system for administration of poorly water soluble pharmaceutically active substances
DK2334378T3 (da)	2008-08-19	2014-07-07	Xenoport Inc	Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
KR101699912B1 (ko)	2009-01-09	2017-01-25	포워드 파마 에이/에스	1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제
JP6385273B6 (ja)	2011-06-08	2023-12-15	バイオジェン・エムエイ・インコーポレイテッド	高純度結晶性ジメチルフマラートの調製方法
JP6088429B2 (ja) *	2011-08-30	2017-03-01	富山化学工業株式会社	関節リウマチなどの自己免疫疾患の治療の改善方法
EP2782561A1 (en)	2011-11-24	2014-10-01	Synthon BV	Controlled release particles comprising dimethyl fumarate
US9504679B2 (en)	2011-12-19	2016-11-29	Bjoern Colin Kahrs	Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en)	2011-12-19	2013-06-20	Ares Trading S.A.	Pharmaceutical compositions
CN113244185A (zh) *	2012-02-07	2021-08-13	比奥根玛公司	含有富马酸二甲酯的药物组合物
JP5918395B2 (ja)	2012-02-07	2016-05-18	ゼノポート，インコーポレイティド	モルホリノアルキルフマレート化合物、医薬組成物及び使用方法
US20140348915A9 (en)	2012-08-22	2014-11-27	Xenoport, Inc.	Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
US20140057918A1 (en) *	2012-08-22	2014-02-27	Xenoport, Inc.	Methods of Use for Monomethyl Fumarate and Prodrugs Thereof
JP2015527372A (ja)	2012-08-22	2015-09-17	ゼノポート，インコーポレイティド	副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
CN103483194B (zh) *	2012-11-30	2016-03-09	杨寅柯	一种2-氟代富马酸酯(结构式i)及其制备方法及应用
JP6506174B2 (ja)	2012-12-21	2019-04-24	バイオジェンエムエーインコーポレイテッド	重水素置換されたフマル酸誘導体
CN105452213B (zh)	2013-03-14	2017-09-22	阿尔克梅斯制药爱尔兰有限公司	富马酸酯前体药物及其在治疗多种疾病中的应用
US8669281B1 (en)	2013-03-14	2014-03-11	Alkermes Pharma Ireland Limited	Prodrugs of fumarates and their use in treating various diseases
WO2014160633A1 (en)	2013-03-24	2014-10-02	Xenoport, Inc.	Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en)	2013-06-07	2016-04-05	Xenoport, Inc.	Method of making monomethyl fumarate
US9421182B2 (en)	2013-06-21	2016-08-23	Xenoport, Inc.	Cocrystals of dimethyl fumarate
TW201516020A (zh)	2013-09-06	2015-05-01	Xenoport Inc	（ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途
CA2940845C (en)	2014-02-24	2019-09-24	Alkermes Pharma Ireland Limited	Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9999672B2 (en)	2014-03-24	2018-06-19	Xenoport, Inc.	Pharmaceutical compositions of fumaric acid esters
WO2016061393A1 (en)	2014-10-15	2016-04-21	Xenoport, Inc.	Fumarate compounds, pharmaceutical compositions, and methods of use
AU2015381240A1 (en) *	2015-02-08	2017-07-06	Alkermes Pharma Ireland Limited	Monomethylfumarate prodrug compositions
EP3273951B1 (en)	2015-03-27	2020-07-29	Symbionyx Pharmaceuticals Inc.	Compositions and methods for treating psoriasis
WO2017060400A1 (en)	2015-10-07	2017-04-13	Neurovive Pharmaceutical Ab	Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
CN106265621B (zh) *	2016-09-19	2019-05-17	苏州大学	富马酸二甲酯在制备预防和治疗移植物抗宿主病及移植物抗白血病药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2530372A1 (de) *	1975-07-08	1977-01-13	Walter Dr Schweckendiek	Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) *	1976-05-13	1981-11-12	Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen	Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
CH664150A5 (de) *	1985-01-15	1988-02-15	Peter Paul Prof Dr Speiser	Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
US5149695A (en) *	1985-01-15	1992-09-22	Speiser Peter P	Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
US4959389A (en) *	1987-10-19	1990-09-25	Speiser Peter P	Pharmaceutical preparation for the treatment of psoriatic arthritis
US5424332A (en) *	1987-10-19	1995-06-13	Speiser; Peter P.	Pharmaceutical composition and process for the production thereof
MC1999A1 (fr) *	1987-12-18	1990-01-26	Hoffmann La Roche	Composes tricycliques
US6011000A (en) *	1995-03-03	2000-01-04	Perrine; Susan P.	Compositions for the treatment of blood disorders
EP1886677A1 (en)	1996-07-26	2008-02-13	Susan P. Perrine	Use of an inducing agent for the treatment of blood, viral and cellular disorders
WO1998027970A2 (en)	1996-12-24	1998-07-02	National Research Council Of Canada	Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
DE19721099C2 (de) *	1997-05-20	1999-12-02	Fumapharm Ag Muri	Verwendung von Fumarsäurederivaten
DE19814358C2 (de) *	1998-03-31	2002-01-17	Fumapharm Ag Muri	Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn

1998
- 1998-08-31 DE DE19839566A patent/DE19839566C2/de not_active Expired - Fee Related
1999
- 1999-08-20 TR TR2000/02475T patent/TR200002475T2/xx unknown
- 1999-08-20 NZ NZ506573A patent/NZ506573A/xx unknown
- 1999-08-20 RS YUP-588/00A patent/RS49780B/sr unknown
- 1999-08-20 EE EEP200000654A patent/EE05025B1/xx not_active IP Right Cessation
- 1999-08-20 RU RU2001108500/14A patent/RU2210364C2/ru not_active IP Right Cessation
- 1999-08-20 EP EP99944453A patent/EP1107749B1/de not_active Expired - Lifetime
- 1999-08-20 AT AT99944453T patent/ATE241353T1/de not_active IP Right Cessation
- 1999-08-20 CA CA002322188A patent/CA2322188C/en not_active Expired - Fee Related
- 1999-08-20 IL IL13811099A patent/IL138110A0/xx not_active IP Right Cessation
- 1999-08-20 HU HU0101854A patent/HUP0101854A3/hu unknown
- 1999-08-20 DK DK99944453T patent/DK1107749T3/da active
- 1999-08-20 PL PL347359A patent/PL198211B1/pl not_active IP Right Cessation
- 1999-08-20 BR BR9908722-7A patent/BR9908722A/pt not_active Application Discontinuation
- 1999-08-20 WO PCT/EP1999/006110 patent/WO2000012072A2/de not_active Ceased
- 1999-08-20 DE DE59905763T patent/DE59905763D1/de not_active Expired - Fee Related
- 1999-08-20 HK HK02102187.7A patent/HK1040623B/zh not_active IP Right Cessation
- 1999-08-20 AU AU57378/99A patent/AU746958B2/en not_active Ceased
- 1999-08-20 SK SK257-2001A patent/SK286352B6/sk not_active IP Right Cessation
- 1999-08-20 US US09/719,189 patent/US6359003B1/en not_active Expired - Lifetime
- 1999-08-20 ES ES99944453T patent/ES2195609T3/es not_active Expired - Lifetime
- 1999-08-20 JP JP2000571022A patent/JP3553883B2/ja not_active Expired - Fee Related
- 1999-08-20 CN CNB99810485XA patent/CN1195511C/zh not_active Expired - Fee Related
- 1999-08-20 PT PT99944453T patent/PT1107749E/pt unknown
2000
- 2000-08-09 BG BG104679A patent/BG64435B1/bg unknown
- 2000-12-18 NO NO20006462A patent/NO20006462L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2322188A1 (en)	2000-03-09
EP1107749A2 (de)	2001-06-20
WO2000012072A3 (de)	2000-05-04
HK1040623A1 (en)	2002-06-21
DE19839566C2 (de)	2002-01-17
PL198211B1 (pl)	2008-06-30
ES2195609T3 (es)	2003-12-01
HUP0101854A3 (en)	2003-04-28
RU2210364C2 (ru)	2003-08-20
JP3553883B2 (ja)	2004-08-11
DE59905763D1 (de)	2003-07-03
CN1195511C (zh)	2005-04-06
BG64435B1 (en)	2005-02-28
BR9908722A (pt)	2001-10-16
AU5737899A (en)	2000-03-21
EE200000654A (et)	2002-04-15
NZ506573A (en)	2002-10-25
BG104679A (en)	2001-02-28
WO2000012072A2 (de)	2000-03-09
TR200002475T2 (tr)	2001-03-21
RS49780B (sr)	2008-06-05
DE19839566A1 (de)	2000-03-09
AU746958B2 (en)	2002-05-09
NO20006462D0 (no)	2000-12-18
ATE241353T1 (de)	2003-06-15
PT1107749E (pt)	2003-08-29
YU58800A (sh)	2002-03-18
HK1040623B (zh)	2005-08-19
EE05025B1 (et)	2008-06-16
JP2002525276A (ja)	2002-08-13
HUP0101854A2 (hu)	2001-11-28
PL347359A1 (en)	2002-04-08
US6359003B1 (en)	2002-03-19
EP1107749B1 (de)	2003-05-28
IL138110A0 (en)	2001-10-31
NO20006462L (no)	2001-04-30
DK1107749T3 (da)	2003-08-18
SK2572001A3 (en)	2002-05-09
CA2322188C (en)	2004-03-09
CN1316901A (zh)	2001-10-10

Legal Events

Date	Code	Title	Description
2010-05-07	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20090820

Publication	Publication Date	Title
SK2572001A3 (en)	2002-05-09	The use of fumaric acid derivatives in transplant medicine
SK5762001A3 (en)	2002-03-05	Utilisation of dialkylfumarates for treating host-versus-graft reactions and auto-immune diseases
CZ299960B6 (cs)	2009-01-07	Použití derivátu kyseliny fumarové
SK286191B6 (sk)	2008-05-06	Použitie solí monoalkylesterov kyseliny fumarovej
NZ505341A (en)	2002-04-26	Use of alkyl hydrogen fumarates (optionally in combination with dialkyl fumarates) for preparing a pharmaceutical composition in the form of micro-tablets or micro-pellets for treating psoriasis, psoriatic arthritis, neurodermatitis and regional enteritis
RS58800B1 (sr)	2019-07-31	Kompozicije za upotrebu u onkologiji
CZ2001689A3 (cs)	2001-06-13	Použití derivátů kyseliny fumarové v transplantační medicíně
MXPA01002031A (es)	2001-12-04	El uso de derivados de acido fumarico en la medicina de transplante